These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 31897875)

  • 1. Castration-resistant prostate cancer without metastasis at presentation may achieve cancer-specific survival in patients who underwent prior radical prostatectomy.
    Kodama H; Koie T; Oikawa M; Narita T; Tanaka T; Noro D; Iwamura H; Tobisawa Y; Yoneyama T; Hashimoto Y; Ohyama C
    Int Urol Nephrol; 2020 Apr; 52(4):671-679. PubMed ID: 31897875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort.
    Mithal P; Howard LE; Aronson WJ; Terris MK; Cooperberg MR; Kane CJ; Amling C; Freedland SJ
    BJU Int; 2016 Feb; 117(2):244-8. PubMed ID: 26010160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database.
    Moreira DM; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Boffetta P; Freedland SJ
    Cancer; 2014 Jan; 120(2):197-204. PubMed ID: 24127391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
    Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
    Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
    Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
    Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can post-treatment free PSA ratio be used to predict adverse outcomes in recurrent prostate cancer?
    Goldberg H; Glicksman R; Woon D; Hoffman A; Shaikh H; Chandrasekar T; Klaassen Z; Wallis CJD; Ahmad AE; Sanmamed-Salgado N; Qu X; Moraes FY; Diamandis EP; Berlin A; Fleshner NE
    BJU Int; 2021 Jun; 127(6):654-664. PubMed ID: 32926761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients.
    Mauermann J; Fradet V; Lacombe L; Dujardin T; Tiguert R; Tetu B; Fradet Y
    Eur Urol; 2013 Jul; 64(1):19-25. PubMed ID: 22901983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?
    Vidal AC; Howard LE; De Hoedt A; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Lechpammer S; Flanders SC; Freedland SJ
    Cancer; 2019 Feb; 125(3):434-441. PubMed ID: 30427535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does surgery benefit patients with oligometastatic or metastatic prostate cancer? - A retrospective cohort study and meta-analysis.
    Si S; Zheng B; Wang Z; Niu Z
    Prostate; 2021 Aug; 81(11):736-744. PubMed ID: 34056739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
    Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
    Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Salvage Radical Prostatectomy for M0 Castration-resistant Recurrent Prostate Cancer: A Reasonable Option in the Era of New Antiandrogen Therapies?
    Marra G; Calleris G; Alessio P; Oderda M; Palou J; Joniau S; Piechaud T; Smelzo S; Morlacco A; Sharma V; Tilki D; Van der Poel H; Veerman H; Karnes RJ; Gontero P
    Eur Urol Focus; 2021 Jul; 7(4):807-811. PubMed ID: 32414618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database.
    Nik-Ahd F; Howard LE; Eisenberg AT; Aronson WJ; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Freedland SJ
    Cancer; 2019 Aug; 125(16):2861-2867. PubMed ID: 31034601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer-specific survival and predictors of prostate-specific antigen recurrence and survival in patients with seminal vesicle invasion after radical prostatectomy.
    Secin FP; Bianco FJ; Vickers AJ; Reuter V; Wheeler T; Fearn PA; Eastham JA; Scardino PT
    Cancer; 2006 Jun; 106(11):2369-75. PubMed ID: 16649221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Significance of Radical Prostatectomy in Clinical Lymph Node Metastasis in Prostate Cancer.
    Kim D; Lim B; Suh J; You D; Jeong IG; Hong JH; Ahn H
    Ann Surg Oncol; 2023 Nov; 30(12):7903-7909. PubMed ID: 37689608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
    Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
    Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
    Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
    Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Prostate Cancer Upgrading and Upstaging on Biochemical Recurrence and Cancer-Specific Survival.
    Bakavičius A; Drevinskaitė M; Daniūnaitė K; Barisienė M; Jarmalaitė S; Jankevičius F
    Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32033148
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.